Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Int J Dermatol. 2023 Jun;62(6):759-763. doi: 10.1111/ijd.16582. Epub 2023 Feb 15.
Seborrheic dermatitis is a common, chronic, and recurrent inflammatory skin disease. There are few studies on oral isotretinoin in the treatment of seborrheic dermatitis. The aim of this research was to analyze the efficacy and safety of oral isotretinoin in the treatment of patients with moderate to severe seborrheic dermatitis.
This was a retrospective study. All included patients were diagnosed as moderate to severe seborrheic dermatitis and treated with oral isotretinoin from January 2019 to December 2020. Symptom Scale of Seborrheic Dermatitis (SSSD) was used to evaluate the overall severity status of disease.
A total of 48 patients with moderate to severe seborrheic dermatitis were enrolled, of which 26 patients were treated with oral isotretinoin at a dose of 20 mg/day, and 22 patients were treated with oral isotretinoin at a dose of 10 mg/day. The duration of treatment was 2.42 ± 0.98 months (range: 2-6 months). The absolute SSSD values were 10.63 ± 1.02 for all 48 patients, 10.95 ± 1.15 and 10.30 ± 1.11 for patients with a dose of 20 and 10 mg/day, respectively. At the endpoint, there were no significant difference in SSSD values between the two groups (2.21 ± 0.24 vs. 2.35 ± 0.46, P = 0.18). The patients were satisfied with the two treatment schemes, and the difference was not statistically significant (P = 0.78). The most common side effect was cheilitis; however, no serious adverse events occurred in either group.
When considering efficacy and safety, oral isotretinoin can be used to treat patients with moderate to severe seborrheic dermatitis.
脂溢性皮炎是一种常见的慢性复发性炎症性皮肤病。关于口服异维 A 酸治疗脂溢性皮炎的研究较少。本研究旨在分析口服异维 A 酸治疗中重度脂溢性皮炎患者的疗效和安全性。
这是一项回顾性研究。所有纳入的患者均被诊断为中重度脂溢性皮炎，并于 2019 年 1 月至 2020 年 12 月接受口服异维 A 酸治疗。采用脂溢性皮炎症状评分量表（SSSD）评估疾病的整体严重程度状况。
共纳入 48 例中重度脂溢性皮炎患者，其中 26 例患者口服异维 A 酸 20mg/d，22 例患者口服异维 A 酸 10mg/d。治疗持续时间为 2.42±0.98 个月（范围：2-6 个月）。48 例患者的绝对 SSSD 值均为 10.63±1.02，剂量为 20mg/d 和 10mg/d 的患者的 SSSD 值分别为 10.95±1.15 和 10.30±1.11。在终点时，两组 SSSD 值无显著差异（2.21±0.24 vs. 2.35±0.46，P=0.18）。两组患者均对两种治疗方案满意，差异无统计学意义（P=0.78）。最常见的不良反应是唇炎，但两组均未发生严重不良事件。
考虑到疗效和安全性，口服异维 A 酸可用于治疗中重度脂溢性皮炎患者。
